Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as ...

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...

We recently published 10 Big Names Get Slammed. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the biggest losers on ...

Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular ...

Arrowhead Pharmaceuticals (ARWR) stock gains as company reassures investors about financial obligations required from Sarepta ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics.

Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (ARWR-11.09%) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

Arrowhead Pharmaceuticals recently received a rating upgrade from SVB Financial and a price target that implies a 44% gain up ahead. Arrowhead Pharmaceuticals is a precommercial-stage drugmaker ...

It is a rough day to be an investor in Arrowhead Pharmaceuticals (NASDAQ: ARWR). Shares of the clinical-stage biotech are collapsing, falling more than 65% as of 11:36 a.m. EST on Tuesday in ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is currently a tremendous value at an over 40% discount to recent highs.A recent upgrade by independent analyst BioBoyScout gives a perfectly ...

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...